Purpose: In a placebo-controlled, double-blind, randomized clinical trial, the effect of an insoluble yeast beta-glucan preparation on the incidences of common colds and its effect on common cold symptoms were compare...Purpose: In a placebo-controlled, double-blind, randomized clinical trial, the effect of an insoluble yeast beta-glucan preparation on the incidences of common colds and its effect on common cold symptoms were compared to placebo. Methods: 100 healthy participants with recurring infections were randomly assigned to receive either placebo or yeast beta-glucan (Yestimun?;n = 50 each group) over a period of 26 weeks. The subjects had to document each common cold episode in a diary, and rate 6 predefined infections symptoms on a 3-point rating scale during an infection period, resulting in an infection score. The common cold episodes were confirmed by the investigators. Results: A total of 171 common cold episodes were documented. Of these, 76 were experienced by 38 subjects in the beta-glucan group and 96 were experienced by 48 subjects in the placebo group (p = 0.406). The beta-glucan group had significantly more subjects without incidences of common cold than the placebo group (15.6% vs 2.0%;p = 0.019). During the most intense infection season (first 13 weeks of the study), the beta-glucan group had significantly less infections compared to placebo (p = 0.02). Beta-glucan significantly reduced the typical cold symptoms (“sore throat and/or difficulty swallowing”, “hoarseness and/or cough” and “runny nose”) as opposed to placebo. Conclusion: The present study demonstrates a prophylactic effect of yeast beta-glucan on the occurrence of common colds as opposed to placebo. In addition, when these episodes occurred, they were from the beginning less pronounced and subsided faster.展开更多
After proving safety in animal and human models, a series of clinical trials were conducted to examine the administration of 1 mg/mL bid of an undenatured beta-glucan on the immune system;and on self-perceived effects...After proving safety in animal and human models, a series of clinical trials were conducted to examine the administration of 1 mg/mL bid of an undenatured beta-glucan on the immune system;and on self-perceived effects on subjects’ quality of life (QoL) using a Visual Analogue Scale (VAS). In one study, a subject population that was self-perceived to be fatigued was administered an undetaured beta-glucan, to determine if this supplementation affected their quality-of-life as a result of an increased immune system response. 44 subjects were administered 1 mg/mL bid of the undenatured beta-glucan (Lentinex<sup>®</sup>) for four weeks. Prior to the beginning of the administration, and following the four-week administration period, the subjects were asked to fill out a quality-of-life VAS questionnaire. The changes in the two questionnaires revealed differences that occurred as a result of the beta-glucan administration. More than 75% of the subjects scored “better” (more than 1 cm on the VAS) with regard to feeling in a good mood, and feeling rested. More than 60% increased their energy and reduced their tiredness and exhaustion, and 70% felt less stressed. In a second study, subjects aged 40 years and older, believed to be in good general health, seeking therapy for tiredness/exhaustion/fatigue or similar conditions (neurasthenia) which were administered 1 mg/mL bid Lentinex<sup>®</sup>. The overall results indicated that the subjects felt significantly better (mean VAS = 5.91) after the last week of the study compared to how they felt initially (VAS = 4.73) (p < 0.0001). A statistically significant (p < 0.0001) change in distribution favoring a better situation after 4 weeks intake of supplement, with a remarkable fall in number of subjects scoring below normal (from 61.4% to 18.2%) accompanied by a significant shift in subjects feeling above normal, from 9.2% to 50.0%. These clinical studies, and others, showed that Lentinex<sup>®</sup> administration improved the perceived quality-of-life of subjects whose immune system was probably not functioning at optimal levels.展开更多
Lack of dietary fiber contributes to many health issues, particularly chronic vascular diseases. Mixed linkage β-1.3 - 1.4 beta-glucan (beta-glucan, in this paper) is a confirmed beneficial ingredient for the human d...Lack of dietary fiber contributes to many health issues, particularly chronic vascular diseases. Mixed linkage β-1.3 - 1.4 beta-glucan (beta-glucan, in this paper) is a confirmed beneficial ingredient for the human diet through reduction of cholesterol and the glycemic index. Barley contains the highest beta-glucan content of all the grains, and in this study, a percentage of flour from two high beta glucan lines was, each, added to an array of wheat-based food products to measure how it impacted total dietary fiber. Results showed that beta-glucan content was higher in all the products containing the added high beta-glucan flour, along with increased total dietary fiber content. Protein content in the food products is also increased with the higher protein in the barley flours added. Beta-glucan content in the barley-added products increased to 1.2% - 4.0% versus 0.2% - 0.5% in the pure wheat products, while the dietary fibers increased to 3.5% - 24.4% versus 2.1% - 9.1% in pure wheat product controls. This research provided experimental evidence that using a high beta-glucan barley ingredient in food can increase dietary fiber to benefit health.展开更多
Exogenous enzymes as alternatives to feed antibiotics in poultry has become an emerging research area with the emergence of antibiotic resistance.The objective was to evaluate the effects of diet medication(antibiotic...Exogenous enzymes as alternatives to feed antibiotics in poultry has become an emerging research area with the emergence of antibiotic resistance.The objective was to evaluate the effects of diet medication(antibiotics)andβ-glucanase(BGase)on digesta solubleβ-glucan depolymerization,carbohydrate fermentation,and performance of coccidiosis-vaccinated broiler chickens fed wheat-based diets.A total of 1,782 broilers were raised on litter floor pens,and each treatment was assigned to 1 pen in each of the9 rooms.The 3 dietary treatments were based on wheat as the sole grain(control,control+medication and control+0.1%BGase),and the birds were fed the respective treatments ad libitum from 0 to 33 d.Treatments were arranged in a randomized complete block design and analyzed as a one-way ANOVA.Beta-glucanase reduced the peak molecular weight,weight average molecular weight(Mw)and maximum molecular weight for the smallest 10%β-glucan molecules(MW-10%)in ileal digesta at d 11and 33,whereas diet medication reduced Mw and MW-10%at d 33 compared to the control(P<0.01).Beta-glucanase and medication reduced the ileal viscosity at d 11 compared to the control(P=0.010).Ileal propionic acid concentration at d 11 and caecal total SCFA,acetic,and butyric acid concentrations at d 33 were lower in the BGase-supplemented diet than in the control(P<0.05).The BGase-added diet had higher duodenal p H compared to the control at d 33(P=0.026).The effect of medication on carbohydrate fermentation was minimal.Diet medication increased weight gain after d 11,whereas BGase increased the gain for the total trial period compared to the control(P<0.001).Feed intake was not affected by the dietary treatment.Medication and BGase improved feed efficiency after d 11 compared to the control(P<0.001).The response to diet medication was larger than BGase,considering weight gain and feed efficiency after d 11(P<0.001).In conclusion,diet medication and BGase depolymerized high molecular weight ileal solubleβ-glucan and increased overall bird performance.Dietary BGase may benefit bird health in broilers fed wheat-based diets without medication.展开更多
目的研究β-葡聚糖对单核细胞释放动脉粥样硬化致病因子[肿瘤坏死因子α(TNF-α)、白细胞介素18(IL-8)和白细胞介素12(IL-12)]的影响。方法用密度梯度离心法分离健康志愿者新鲜血液中的单核细胞,使用佛波醇酯(PMA)诱导单核细胞分化为巨...目的研究β-葡聚糖对单核细胞释放动脉粥样硬化致病因子[肿瘤坏死因子α(TNF-α)、白细胞介素18(IL-8)和白细胞介素12(IL-12)]的影响。方法用密度梯度离心法分离健康志愿者新鲜血液中的单核细胞,使用佛波醇酯(PMA)诱导单核细胞分化为巨噬细胞,进一步利用氧化低密度脂蛋白(ox-LDL)诱导巨噬细胞为泡沫细胞,将实验分为无药对照组、ox-LDL组、颗粒性β-葡聚糖(WGP)组和WGP+ox-LDL组,提取总RNA,扩增TNF-α、IL-8和IL-12 c DNA,并采用酶联免疫吸附试验(ELISA)测定细胞上清液中的浓度。结果与无药对照组比较,ox-LDL诱导单核细胞TNF-α、IL-8和IL-12蛋白水平的表达显著升高(P<0.05),而WGP可以显著抑制ox-LDL诱导的上述细胞因子在蛋白水平和TNF-α、IL-8在mRNA水平的表达(P<0.05)。结论β-葡聚糖可能通过抑制单核细胞促炎因子的分泌减缓动脉粥样硬化形成。展开更多
文摘Purpose: In a placebo-controlled, double-blind, randomized clinical trial, the effect of an insoluble yeast beta-glucan preparation on the incidences of common colds and its effect on common cold symptoms were compared to placebo. Methods: 100 healthy participants with recurring infections were randomly assigned to receive either placebo or yeast beta-glucan (Yestimun?;n = 50 each group) over a period of 26 weeks. The subjects had to document each common cold episode in a diary, and rate 6 predefined infections symptoms on a 3-point rating scale during an infection period, resulting in an infection score. The common cold episodes were confirmed by the investigators. Results: A total of 171 common cold episodes were documented. Of these, 76 were experienced by 38 subjects in the beta-glucan group and 96 were experienced by 48 subjects in the placebo group (p = 0.406). The beta-glucan group had significantly more subjects without incidences of common cold than the placebo group (15.6% vs 2.0%;p = 0.019). During the most intense infection season (first 13 weeks of the study), the beta-glucan group had significantly less infections compared to placebo (p = 0.02). Beta-glucan significantly reduced the typical cold symptoms (“sore throat and/or difficulty swallowing”, “hoarseness and/or cough” and “runny nose”) as opposed to placebo. Conclusion: The present study demonstrates a prophylactic effect of yeast beta-glucan on the occurrence of common colds as opposed to placebo. In addition, when these episodes occurred, they were from the beginning less pronounced and subsided faster.
文摘After proving safety in animal and human models, a series of clinical trials were conducted to examine the administration of 1 mg/mL bid of an undenatured beta-glucan on the immune system;and on self-perceived effects on subjects’ quality of life (QoL) using a Visual Analogue Scale (VAS). In one study, a subject population that was self-perceived to be fatigued was administered an undetaured beta-glucan, to determine if this supplementation affected their quality-of-life as a result of an increased immune system response. 44 subjects were administered 1 mg/mL bid of the undenatured beta-glucan (Lentinex<sup>®</sup>) for four weeks. Prior to the beginning of the administration, and following the four-week administration period, the subjects were asked to fill out a quality-of-life VAS questionnaire. The changes in the two questionnaires revealed differences that occurred as a result of the beta-glucan administration. More than 75% of the subjects scored “better” (more than 1 cm on the VAS) with regard to feeling in a good mood, and feeling rested. More than 60% increased their energy and reduced their tiredness and exhaustion, and 70% felt less stressed. In a second study, subjects aged 40 years and older, believed to be in good general health, seeking therapy for tiredness/exhaustion/fatigue or similar conditions (neurasthenia) which were administered 1 mg/mL bid Lentinex<sup>®</sup>. The overall results indicated that the subjects felt significantly better (mean VAS = 5.91) after the last week of the study compared to how they felt initially (VAS = 4.73) (p < 0.0001). A statistically significant (p < 0.0001) change in distribution favoring a better situation after 4 weeks intake of supplement, with a remarkable fall in number of subjects scoring below normal (from 61.4% to 18.2%) accompanied by a significant shift in subjects feeling above normal, from 9.2% to 50.0%. These clinical studies, and others, showed that Lentinex<sup>®</sup> administration improved the perceived quality-of-life of subjects whose immune system was probably not functioning at optimal levels.
文摘Lack of dietary fiber contributes to many health issues, particularly chronic vascular diseases. Mixed linkage β-1.3 - 1.4 beta-glucan (beta-glucan, in this paper) is a confirmed beneficial ingredient for the human diet through reduction of cholesterol and the glycemic index. Barley contains the highest beta-glucan content of all the grains, and in this study, a percentage of flour from two high beta glucan lines was, each, added to an array of wheat-based food products to measure how it impacted total dietary fiber. Results showed that beta-glucan content was higher in all the products containing the added high beta-glucan flour, along with increased total dietary fiber content. Protein content in the food products is also increased with the higher protein in the barley flours added. Beta-glucan content in the barley-added products increased to 1.2% - 4.0% versus 0.2% - 0.5% in the pure wheat products, while the dietary fibers increased to 3.5% - 24.4% versus 2.1% - 9.1% in pure wheat product controls. This research provided experimental evidence that using a high beta-glucan barley ingredient in food can increase dietary fiber to benefit health.
文摘Exogenous enzymes as alternatives to feed antibiotics in poultry has become an emerging research area with the emergence of antibiotic resistance.The objective was to evaluate the effects of diet medication(antibiotics)andβ-glucanase(BGase)on digesta solubleβ-glucan depolymerization,carbohydrate fermentation,and performance of coccidiosis-vaccinated broiler chickens fed wheat-based diets.A total of 1,782 broilers were raised on litter floor pens,and each treatment was assigned to 1 pen in each of the9 rooms.The 3 dietary treatments were based on wheat as the sole grain(control,control+medication and control+0.1%BGase),and the birds were fed the respective treatments ad libitum from 0 to 33 d.Treatments were arranged in a randomized complete block design and analyzed as a one-way ANOVA.Beta-glucanase reduced the peak molecular weight,weight average molecular weight(Mw)and maximum molecular weight for the smallest 10%β-glucan molecules(MW-10%)in ileal digesta at d 11and 33,whereas diet medication reduced Mw and MW-10%at d 33 compared to the control(P<0.01).Beta-glucanase and medication reduced the ileal viscosity at d 11 compared to the control(P=0.010).Ileal propionic acid concentration at d 11 and caecal total SCFA,acetic,and butyric acid concentrations at d 33 were lower in the BGase-supplemented diet than in the control(P<0.05).The BGase-added diet had higher duodenal p H compared to the control at d 33(P=0.026).The effect of medication on carbohydrate fermentation was minimal.Diet medication increased weight gain after d 11,whereas BGase increased the gain for the total trial period compared to the control(P<0.001).Feed intake was not affected by the dietary treatment.Medication and BGase improved feed efficiency after d 11 compared to the control(P<0.001).The response to diet medication was larger than BGase,considering weight gain and feed efficiency after d 11(P<0.001).In conclusion,diet medication and BGase depolymerized high molecular weight ileal solubleβ-glucan and increased overall bird performance.Dietary BGase may benefit bird health in broilers fed wheat-based diets without medication.
文摘目的研究β-葡聚糖对单核细胞释放动脉粥样硬化致病因子[肿瘤坏死因子α(TNF-α)、白细胞介素18(IL-8)和白细胞介素12(IL-12)]的影响。方法用密度梯度离心法分离健康志愿者新鲜血液中的单核细胞,使用佛波醇酯(PMA)诱导单核细胞分化为巨噬细胞,进一步利用氧化低密度脂蛋白(ox-LDL)诱导巨噬细胞为泡沫细胞,将实验分为无药对照组、ox-LDL组、颗粒性β-葡聚糖(WGP)组和WGP+ox-LDL组,提取总RNA,扩增TNF-α、IL-8和IL-12 c DNA,并采用酶联免疫吸附试验(ELISA)测定细胞上清液中的浓度。结果与无药对照组比较,ox-LDL诱导单核细胞TNF-α、IL-8和IL-12蛋白水平的表达显著升高(P<0.05),而WGP可以显著抑制ox-LDL诱导的上述细胞因子在蛋白水平和TNF-α、IL-8在mRNA水平的表达(P<0.05)。结论β-葡聚糖可能通过抑制单核细胞促炎因子的分泌减缓动脉粥样硬化形成。
